Integra Lifesciences Holdings (IART) Total Debt (2009 - 2026)

Integra Lifesciences Holdings' Total Debt history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Total Debt rose 53.26% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 53.26% YoY), while the FY2025 annual figure was $1.8 billion, up 6.45% from the prior year.
• Total Debt came in at $1.8 billion for Q1 2026 at Integra Lifesciences Holdings, up from $1.8 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.8 billion in Q1 2026 to a low of $769.1 million in Q1 2023.
• A 5-year average of $1.1 billion and a median of $1.2 billion in 2025 frame the typical range for Total Debt.
• Across the five-year window, Total Debt decreased 11.58% in 2023 and surged 101.21% in 2024, its largest moves.
• Integra Lifesciences Holdings' Total Debt stood at $771.3 million in 2022, then grew by 7.04% to $825.6 million in 2023, then soared by 101.21% to $1.7 billion in 2024, then climbed by 6.45% to $1.8 billion in 2025, then grew by 1.17% to $1.8 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $1.8 billion, $1.8 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison